Program
Ranibizumab
Also written as “ranibizumab”, “Ranibizumab 0.5 mg” and “rhuFab V2 (ranibizumab)”.
Its studies are mostly in Macular Degeneration · Macular Edema · Choroidal Neovascularization · Retinal Vein Occlusion · Vision Disorders, led by 16 companies.
Drug pageRanibizumab: every studyMany companies study it; this page follows only the 98 they lead. All 351 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 560 open or running | phase 4since Jul 19, 2007 | Jan 11, 2006 | none ahead |
| Hoffmann-La Roche | 244 open or running | phase 4since Jan 13, 2011 | Mar 24, 2003 | Feb 4, 2027phase 3 · NCT04657289 |
| AbbVieits history only | 31 open or running | phase 4since Aug 31, 2011 | Oct 16, 2008 | Jul 2031phase 2 · NCT05210803 |
| Samsung Bioepisits history only | 20 open or running | phase 2since Dec 11, 2023 | Dec 11, 2023 | none ahead |
| Santen Pharmaceuticalits history only | 20 open or running | phase 2since Oct 1, 2008 | Oct 1, 2008 | none ahead |
| AO GENERIUMits history only | 11 open or running | phase 3since Nov 30, 2020 | Nov 30, 2020 | none ahead |
| bioeq-gmbhits history only | 10 open or running | phase 3since Nov 19, 2015 | Nov 19, 2015 | none ahead |
| Cynosure Lutronicits history only | 10 open or running | phase 4since Nov 27, 2018 | Nov 27, 2018 | none ahead |
| Formyconits history only | 10 open or running | phase 4since Nov 25, 2024 | Nov 25, 2024 | none ahead |
| Incepta Pharmaceuticalsits history only | 10 open or running | phase 3since Mar 5, 2024 | Mar 5, 2024 | none ahead |
| oraya-therapeutics-incits history only | 10 open or running | no phasesince Jan 24, 2012 | Jan 24, 2012 | none ahead |
| pfenex-incits history only | 10 open or running | phase 2since Apr 17, 2014 | Apr 17, 2014 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 1since Oct 12, 2017 | Oct 12, 2017 | none ahead |
| qlt-incits history only | 10 open or running | phase 2since Jun 25, 2007 | Jun 25, 2007 | none ahead |
| shanghai-biomabs-pharmaceutical-co-ltdits history only | 10 open or running | phase 1since May 6, 2021 | May 6, 2021 | none ahead |
| xbrane-biopharma-abits history only | 10 open or running | phase 3since Jan 8, 2019 | Jan 8, 2019 | none ahead |
Also a collaborator on its studies: REGENXBIO, Stada Arzneimittel and MacuSight.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Mar 24, 2003.
- Jun 11, 20072 phase 3 studies in Macular EdemaNCT00486018, NCT00485836
- Apr 29, 2009Phase 3 study in Macular DegenerationNCT00891735 · 1,097 enrolled · United States
- Jan 13, 2011Phase 4 study in Macular EdemaNCT01277302 · 202 enrolled · United States
- Sep 26, 2011No phase study in Macular EdemaNCT01442064 · 608 enrolled
- Jun 12, 2015Phase 2 study in Choroidal NeovascularizationNCT02484690 · 273 enrolled · United States
- Jul 17, 2015Phase 2 study in Macular DegenerationNCT02510794 · 225 enrolled · United States
- Feb 29, 2016Phase 3 study in Macular EdemaNCT02698566 · 35 enrolled · United States
- Aug 5, 2020Phase 3 study in Diabetic RetinopathyNCT04503551 · 174 enrolled · United States, Puerto Rico
- Sep 24, 2020Phase 2 study in Macular DegenerationNCT04567303 · 177 enrolled · United States, Puerto Rico
- Dec 1, 2020Phase 3 study in Neovascular Age-related Macular Degeneration (nAMD)NCT04657289 · 451 enrolled · Argentina, Australia, Austria and more
- Apr 16, 2021Phase 4 study in Neovascular Age-related Macular DegenerationNCT04853251 · 188 enrolled · United States
- Oct 28, 2021Phase 3 study in Neovascular Age-Related Macular DegenerationNCT05126966 · Argentina, Denmark, Greece and more
- Sep 15, 2022Phase 3 study in Neovascular Age-related Macular DegenerationNCT05562947 · 68 enrolled · China
- Feb 21, 2025Phase 3 study in Neovascular Age-related Macular DegenerationNCT06847542 · 250 planned · Austria, Czechia, Denmark and more
Ahead
- Feb 4, 2027Primary completion: phase 3 study in Neovascular Age-related Macular Degeneration (nAMD)NCT04657289
- Jun 30, 2027Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationNCT05562947
- Jul 30, 2027Primary completion: phase 4 study in Neovascular Age-related Macular DegenerationNCT04853251
- Nov 15, 2028Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationNCT06847542
TargetBeta
“A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha”NCIt, by rule
“Vascular endothelial growth factor A inhibitor”ChEMBL 37, by rule
Other programs on VEGFA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bevacizumabrule | Hoffmann-La Roche | phase 4 | 250 |
| afliberceptrule | Regeneron Pharmaceuticals | phase 4 | 89 |
| faricimabrule | Hoffmann-La Roche | phase 4 | 17 |
| ivonescimabrule | Akeso | phase 3 | 48 |
| pumitamig | BioNTech | phase 3 | 34 |
| tivunatamig | Pfizer | phase 3 | 15 |
| suvemcitugrule | Simcere Pharmaceutical Group | phase 3 | 6 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| surabgene lomparvovec | AbbVie | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
Studies
All 24 Hoffmann-La Roche leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06847542Neovascular Age-related Macular Degeneration · Austria, Czechia, Denmark and more | 3 | Recruiting | Nov 15, 2028 | 250 |
| NCT05562947Neovascular Age-related Macular Degeneration · China | 3 | Active, not recruiting | Jun 30, 2027 | 68 |
| NCT05126966Neovascular Age-Related Macular Degeneration · Argentina, Denmark, Greece and more | 3 | Withdrawn | Jan 31, 2025 | 0 |
| NCT04853251Neovascular Age-related Macular Degeneration · United States | 4 | Active, not recruiting | Jul 30, 2027 | 188 |
| NCT04657289Neovascular Age-related Macular Degeneration (nAMD) · Argentina, Australia, Austria and more | 3 | Active, not recruiting | Feb 4, 2027 | 451 |
| NCT04567303Macular Degeneration · United States, Puerto Rico | 2 | Completed | Aug 25, 2026 | 177 |
| NCT04503551Diabetic Retinopathy · United States, Puerto Rico | 3 | Completed | Oct 3, 2022 | 174 |
| NCT02698566Macular Edema · United States | 3 | Completed | Apr 5, 2016 | 35 |
| NCT02510794Macular Degeneration · United States | 2 | Completed | Apr 10, 2018 | 225 |
| NCT02484690Choroidal Neovascularization · United States | 2 | Completed | Sep 26, 2017 | 273 |
| NCT01442064Macular Edema | – | Completed | Jul 2010 | 608 |
| NCT01277302Macular Edema · United States | 4 | Completed | Oct 2012 | 202 |
| NCT00891735Macular Degeneration · United States | 3 | Completed | Aug 2011 | 1,097 |
| NCT00486018Macular Edema | 3 | Completed | May 2009 | 397 |
| NCT00485836Macular Edema | 3 | Completed | Jun 2009 | 392 |
| NCT00473382Diabetes Mellitus | 3 | Completed | Jan 2011 | 382 |
| NCT00473330Diabetes Mellitus | 3 | Completed | Nov 2010 | 377 |
| NCT00379795Choroidal Neovascularization | – | Completed | Sep 2008 | 853 |
| NCT00251459Choroidal Neovascularization | 3 | Completed | 5,000 | |
| NCT00095433Macular Degeneration | 3 | Completed | Aug 2006 | 100 |
| NCT00090623Macular Degeneration · United States | 3 | Completed | 180 | |
| NCT00061594Macular Degeneration · United States, Australia, Czech Republic and more | 3 | Completed | 426 | |
| NCT00056836Macular Degeneration | 3 | Completed | 720 | |
| NCT00056823Macular Degeneration | 2 | Completed | 168 |
How it is read
Names in the registry
- “Ranibizumab”, 40 entries
- “ranibizumab”, 18 entries
- “Ranibizumab 0.5 mg”, 11 entries
- “rhuFab V2 (ranibizumab)”, 6 entries
- “Ranibizumab 0.5mg”, 4 entries
Conditions, from the studies’ own filings
- Macular Degeneration, 41 studies
- Macular Edema, 22 studies
- Choroidal Neovascularization, 15 studies
- Retinal Vein Occlusion, 7 studies
- Vision Disorders, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.